87 results
DEFM14A
HARP
Harpoon Therapeutics Inc
8 Feb 24
Proxy related to merger
7:00am
&A environment and strategic landscape, including Merck. Also at the meeting, management provided business, portfolio, quality/CMC and financial updates … if it remained independent, including the current and prospective business environment in which Harpoon operates, industry and market conditions negatively
PREM14A
HARP
Harpoon Therapeutics Inc
29 Jan 24
Preliminary proxy related to merger
4:52pm
&A environment and strategic landscape, including Merck. Also at the meeting, management provided business, portfolio, quality/CMC and financial updates … if it remained independent, including the current and prospective business environment in which Harpoon operates, industry and market conditions negatively
DEFA14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy soliciting materials
8:04am
to pollution, the environment, natural resources, or protection of human health and safety from exposure to Hazardous Substances, including any … pollution; (iii) the release or threatened release into the environment of any Hazardous Substance, including emissions, discharges, injections, spills
8-K
EX-2.1
HARP
Harpoon Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
, the environment, natural resources, or protection of human health and safety from exposure to Hazardous Substances, including any of the foregoing … ) the release or threatened release into the environment of any Hazardous Substance, including emissions, discharges, injections, spills, escapes
8-K
EX-10.1
s2h63lu6snz5 6yn
23 Oct 23
Entry into a Material Definitive Agreement
7:45pm
8-K
EX-99.1
cjwpb2 ho
23 Oct 23
Other Events
8:00am
8-K
EX-99.1
rr8k33uqaqwmednhh4
9 Aug 23
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
6chgnny1
11 May 23
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9:07pm
PRE 14A
ijfg0hsgxct52pa9ssch
14 Apr 23
Preliminary proxy
4:54pm
8-K
EX-99.2
mrr cexkaumd979
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
apldkofm
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
2e5i6s6gand1g9hn9l
14 Nov 22
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
5:17pm
8-K
EX-99.1
9qxz43cb7k84f fylf4v
10 Aug 22
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
6byufql2qzh 5m0q3
12 May 22
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:28pm